CRISPR therapeutics inc, logo 2020

Graphic Source: CRISPR Therapeutics, Inc.

Introduction: What is CRISPR Therapeutics, Inc.?

CRISPR Therapeutics (NASDAQ:CRSP) is a gene-editing company focused on the development and versatile application of CRISPR/Cas9 therapeutics, a special brand of therapeutics used for precision genome editing by applying a viral defense mechanism from bacteria to regulate, disrupt, or correct genes related to key diseases. CRSP is currently targeting disease areas, including hemoglobinopathies, oncology, and regenerative medicines.

Founded in 2013 in Switzerland, CRSP has since grown to over 304 employees producing relatively inconsistent revenues ranging from $3M in 2018 to $290M in 2019 with expectations for 2020 at $6.7M. Their lead candidate is CTX001, an investigational autologous gene-edited hematopoietic stem cell therapy developed in partnership with Vertex Pharmaceuticals (NASDAQ:VRTX) for treating transfusion-dependent beta-thalassemia (“TDT”) and severe sickle cell disease (“SCD”).

Products: CRSP’s pipeline consists of 9 therapeutics: 4 in the clinical phase and 5 in the research phase. Of the 4 clinical phase therapeutics, the first targets TDT and SCD (mentioned above: CTX001), while the 3 others fall into immuno-oncology covering: CD19+ malignancies (Product: CTX110), multiple myeloma (CTX120) and solid tumors and hematologic malignancies (CTX130). All immuno-oncology therapeutics are allogeneic CRISPR/Cas9 gene-edited CAR-T cell therapies wholly owned by CRISPR Therapeutics with data updates typically every 6 months.

Customers/market: For CRSP’s clinical phase pipeline, the total estimated 2022 global market potential is $220B with an average market size for each disease of $36.7B growing at an average 15.2% CAGR (median market: $13.3B | CAGR 10.9%). The largest market is Solid Tumors, at a 2022 estimated size of $145B (8.1% CAGR), and the highest CAGR market CAR T/CD19+ market at a 34.5% CAGR. For CTX001, the lead candidate, the target market can be broken down into the TDT market at very roughly $1.8B with a 10.8% CAGR and the SCD market

PRINCETON, N.J.–(BUSINESS WIRE)–
NRG Energy Inc. (NYSE: NRG) announced that on October 7, 2020 the Company received notice from the Department of Justice and the Federal Trade Commission granting early termination of the Hart-Scott-Rodino (HSR) waiting period for the previously announced Direct Energy acquisition.

The Company has received Centrica Shareholder, Canadian Competition Act and HSR approvals. This acquisition remains subject to approval from the Federal Energy Regulatory Commission (FERC).

The acquisition is targeted to close by year end 2020.

About NRG

At NRG, we’re bringing the power of energy to people and organizations by putting customers at the center of everything we do. We generate electricity and provide energy solutions and natural gas to more than 3.7 million residential, small business, and commercial and industrial customers through our diverse portfolio of retail brands. A Fortune 500 company, operating in the United States and Canada, NRG delivers innovative solutions while advocating for competitive energy markets and customer choice, and by working towards a sustainable energy future. More information is available at www.nrg.com. Connect with NRG on Facebook, LinkedIn and follow us on Twitter @nrgenergy, @nrginsight.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “will,” “expects,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. Forward-looking statements include, without limitation, statements about the Direct Energy transaction and the anticipated timing thereof and NRG’s ability to satisfy the conditions with respect to such acquisition; NRG’s indebtedness, capital structure, plans, expectations, objectives and other future events, and views of economic and market conditions. NRG cautions that these statements are based on current estimates of future performance and are highly dependent upon a variety of factors, which could cause actual results to differ from these estimates. Among



a close up of a piece of paper


© Provided by Zee Business


Health Insurance Plans: From 1st October 2020, a lot of changes related to one’s personal finance is changing. These changes will have a direct impact on one’s pocket and regular expenses. Health insurance plans are one such area that is going to change completely from next month i.e. from 1st October 2020. From this date insurance companies won’t be able to reject insurance claims with ease. 

If a health insurance plan holder has paid a policy premium for eight years, then the insurance company can’t reject the insurance claim in the wake of a loophole in the claim. Now a health insurance plan will cover the maximum number of diseases, however, it will lead to a rise in the health insurance policy premium.

See Zee Business Live TV streaming below:

Major changes from 1st October in the insurance sector

1] Coverage of the number of diseases will get increased;

2] Major diseases outside the health insurance policy will be the same for all insurance companies;

3] Major diseases outside health insurance plan will come down to 17 only;

4] If the major diseases outside plan is 10, then health insurance premium will come down as well;

5] If the major diseases outside plan is 30, then health insurance premium for such plans will go up;

6] In new health insurance products, insurance premium is expected to go northward from 5 per cent to 20 per cent;

7] Psychiatric, genetic and neuro diseases will also get covered in health insurance plans;

8] Neuro disorder, oral chemotherapy, robotic surgery and stem cell therapy will also get covered under health insurance plans.

Terms and conditions for pre-exit

1] A disease pointed out by the doctor before 48 months will be considered for pre-existing under the health insurance plan;